Compare Olympus Corp. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 6.47% CAGR growth in Net Sales over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of 6.47% over the last 5 years
3
Flat results in Mar 26
4
With ROE of 11.32%, it has a expensive valuation with a 2.40 Price to Book Value
5
Majority shareholders : Non Institution
6
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,923,602 Million (Large Cap)
21.00
NA
0.00%
0.08
11.09%
2.37
Revenue and Profits:
Net Sales:
295,281 Million
(Quarterly Results - Mar 2026)
Net Profit:
24,815 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.21%
0%
24.21%
6 Months
1.09%
0%
1.09%
1 Year
6.39%
0%
6.39%
2 Years
-21.37%
0%
-21.37%
3 Years
-17.69%
0%
-17.69%
4 Years
-29.2%
0%
-29.2%
5 Years
-18.72%
0%
-18.72%
Olympus Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.47%
EBIT Growth (5y)
13.43%
EBIT to Interest (avg)
21.06
Debt to EBITDA (avg)
0.30
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.96
Tax Ratio
26.43%
Dividend Payout Ratio
48.93%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
22.11%
ROE (avg)
17.09%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.40
EV to EBIT
12.32
EV to EBITDA
8.54
EV to Capital Employed
2.32
EV to Sales
1.92
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
18.87%
ROE (Latest)
11.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
295,281.00
272,111.00
8.51%
Operating Profit (PBDIT) excl Other Income
69,965.00
77,321.00
-9.51%
Interest
516.00
544.00
-5.15%
Exceptional Items
-23,885.00
-3,569.00
-569.24%
Consolidate Net Profit
24,815.00
41,443.00
-40.12%
Operating Profit Margin (Excl OI)
180.90%
220.80%
-3.99%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 8.51% vs 4.46% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -40.12% vs 112.70% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
1,010,676.00
997,332.00
1.34%
Operating Profit (PBDIT) excl Other Income
214,226.00
254,604.00
-15.86%
Interest
9,284.00
4,821.00
92.57%
Exceptional Items
-41,808.00
-24,004.00
-74.17%
Consolidate Net Profit
68,172.00
117,800.00
-42.13%
Operating Profit Margin (Excl OI)
145.50%
188.70%
-4.32%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 1.34% vs 7.73% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -42.13% vs 235.95% in Mar 2025
About Olympus Corp. 
Olympus Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






